Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects
Completed
VGX Pharmaceuticals, LLC
Phase 2
2006-07-01
The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1
activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at
each dose level.
The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors
Terminated
University of Southern California
N/A
2004-09-01
The purpose of this study is to determine the effect of mifepristone on the expression of
three cervical EP3 receptor isoforms (EP3-2, EP3-3 and EP3-6) in pregnant women ≤63 days
gestational age.
Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
Completed
Eric Lenze
Phase 1/Phase 2
2012-09-01
This study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive
impairment in older adults with anxiety disorders. Anxiety disorders are common, severe, and
disabling in older adults. One particularly impairing aspect of late-life anxiety disorders
is cognitive impairment: impairments in memory and executive function cause disability,
impede treatment response to psychotherapy, may lead to dementia, and are not corrected by
standard anti-anxiety treatments.
This pilot study will test the glucocorticoid antagonist, mifepristone, for cognitive
impairment in late-life anxiety disorders. Mifepristone blocks the effects of elevated
cortisol levels on glucocorticoid receptors in the brain; it has been studied preliminarily
in various neuropsychiatric disorders, such as psychotic depression and bipolar disorder,
with well-documented safety and tolerability.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
